文献速递妇科

肿瘤大于2cm及4cm的宫颈癌患者的前哨淋巴结活检

SLN biopsy in cervical cancer patients with tumors larger than 2cm and 4cm.
PubMed 文献 · Gynecol Oncol · 2018-02-01

该回顾性分析纳入350例pT1a-pT2期宫颈癌患者,评估前哨淋巴结(SLN)活检在肿瘤大于2cm时的检出率、假阴性率和敏感性。结果显示,调整示踪剂注射技术后,肿瘤<2cm、2-3.9cm和≥4cm三组的双侧检出率、假阴性率和敏感性均无显著差异。

要点

  • 肿瘤<2cm、2-3.9cm和≥4cm三组的双侧SLN检出率分别为79%、83%、76%,差异无统计学意义(P=0.460)。
  • 三组假阴性率分别为0.9%、0.9%、0.0%,差异无统计学意义(P=0.999)。
  • 全组敏感性达96%,三组敏感性分别为93%、93%、100%,差异无统计学意义(P=0.510)。

核心结论

  • 若在较大肿瘤中调整示踪剂应用技术,SLN活检在肿瘤小于和大于2cm的盆腔淋巴结分期中同样可靠。
  • 肿瘤<2cm、2-3.9cm和≥4cm亚组的双侧检出率和假阴性率无差异。

研究设计与样本

  • 回顾性分析。
  • 纳入350例pT1a-pT2期宫颈癌患者,均接受手术治疗,包括SLN活检后行系统性盆腔淋巴结切除术。
  • 采用蓝染料和放射性胶体联合技术,在较大肿瘤中修改为将示踪剂注射至残余宫颈间质。

主要发现

  • 大转移、微转移和孤立肿瘤细胞分别占10%、8%和4%。
  • 肿瘤<2cm、2-3.9cm和≥4cm亚组的双侧检出率分别为79%、83%、76%(P=0.460)。
  • 双侧SLN检出者中,仅2例SLN超分期对盆腔淋巴结状态假阴性。
  • 肿瘤<2cm、2-3.9cm和≥4cm亚组的假阴性率分别为0.9%、0.9%、0.0%(P=0.999)。
  • 全组敏感性96%,三组敏感性分别为93%、93%、100%(P=0.510)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to assess the detection rate, false-negative rate and sensitivity of SLN in LN staging in tumors over 2cm on a large cohort of patients. METHODS: Data from patients with stages pT1a - pT2 cervical cancer who underwent surgical treatment, including SLN biopsy followed by systematic pelvic lymphadenectomy, were retrospectively analyzed. A combined technique with blue dye and radiocolloid was modified in larger tumors to inject the tracer into the residual cervical stroma. RESULTS: The study included 350 patients with stages pT1a - pT2. Macrometastases, micrometastases, and isolated tumor cells were found in 10%, 8%, and 4% of cases. Bilateral detection rate was similar in subgroups with tumors<2cm, 2-3.9cm, and ≥4cm (79%, 83%, 76%) (P=0.460). There were only two cases with false-negative SLN ultrastaging for pelvic LN status among those with bilateral SLN detection. The false negative rate was very low in all three subgroups of different tumor sizes (0.9%, 0.9%, and 0.0%; P=0.999). Sensitivity reached 96% in the whole group and was high in all three groups (93%, 93%, 100%; P=0.510). CONCLUSIONS: If the tracer application technique is adjusted in larger tumors, SLN biopsy can be equally reliable in pelvic LN staging in tumors smaller and larger than 2cm. The bilateral detection rate and false negative rate did not differ in subgroups of patients with tumors<2cm, 2-3.9cm, and ≥4cm.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Dostálek L, Zikan M, Fischerova D, et al. SLN biopsy in cervical cancer patients with tumors larger than 2cm and 4cm. Gynecol Oncol. 2018. PMID: 29366509. doi:10.1016/j.ygyno.2018.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。